CANbridge Pharmaceuticals Inc. (1228.HK)

0.340 +0.005 (+1.49%) As of 11:45AM HKT. Market open.

CANbridge Pharmaceuticals Inc.

Suzhou Industrial Park, Building 21
Unit 18, 6th Floor No. 388 Xinping Street
Suzhou
China
86 10 6478 0016
https://www.canbridgepharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 100

Key executives

Name	Title	Pay	Exercised	Year born
Dr. James Qun Xue M.B.A., Ph.D.	Founder, Chairman of the Board, CEO & Member of Strategic Advisory Board	6.43M	N/A	1970
Mr. Glenn Hassan	Chief Financial Officer	N/A	N/A	1979
Dr. Pauline Li M.B.A., M.D.	Senior VP of Clinical Development & Operations	N/A	N/A	N/A
Ms. Qian Ma	Director of Legal & Compliance, Board Secretary and Joint Company Secretary	N/A	N/A	N/A
Ms. Stella Mao	Senior Director of Public Affairs	N/A	N/A	N/A
Ms. Chris Chen	Vice President of Human Resources	N/A	N/A	N/A
Dr. Gerald F. Cox M.D., Ph.D.	Chief Development Strategist & Interim Chief Medical Officer	N/A	N/A	1959
Mr. Marcelo Cheresky	Chief Commercial Officer	N/A	N/A	1966
Dr. Wei Zhang	Senior Director & Head of CMC China	N/A	N/A	N/A
Ms. Rebecca Zhang	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Livmarli, an oral, minimally-absorbed, reversible IBAT inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also engages in the development of CAN008, a CD95-Fc fusion protein that is in Phase 2/3 clinical trial for the treatment of glioblastoma multiforme; CAN106, an anti-C5 mAb that has completed Phase I clinical trial for paroxysmal nocturnal hemoglobinuria; and CAN103, a recombinant human enzyme replacement therapy (ERT) that is in Phase 2/3 clinical trials for gaucher disease. In addition, the company develops CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody for X-linked hypophosphatemia; CAN104, a recombinant human ERT GLA for fabry disease; CAN105, a bispecific antibody for the treatment of hemophilia A; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; CAN202, a gene therapy program utilizing AAV sL65 capsid for pompe disease; and CAN 203, a gene therapy program that utilizes AAV SMN1 for the treatment of spinal muscular atrophy. It has a license agreement with Mirum for the development, commercialization, and manufacturing, under certain conditions, of Livmarli. CANbridge Pharmaceuticals Inc. was founded in 2012 and is headquartered in Suzhou, China.

Corporate governance

CANbridge Pharmaceuticals Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.